VolitionRX Limited (VNRX)

NYSEAMERICAN: VNRX · IEX Real-Time Price · USD
2.61
-0.09 (-3.33%)
May 18, 2022 4:00 PM EDT - Market closed
Market Cap140.54M
Revenue (ttm)178,716
Net Income (ttm)-28.33M
Shares Out53.85M
EPS (ttm)-0.51
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume48,803
Open2.70
Previous Close2.70
Day's Range2.56 - 2.70
52-Week Range2.08 - 4.14
Beta1.72
AnalystsBuy
Price Target7.75 (+196.9%)
Earnings DateMay 12, 2022

About VNRX

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company operates Nucleosomics a technology platform for blood test. VolitionRx Limited is based in Austin, Texa...

IndustryHealth Care Equipment & Supplies
Employees83
Stock ExchangeNYSEAMERICAN
Ticker SymbolVNRX
Full Company Profile

Financial Performance

In 2021, VolitionRX's revenue was $90,035, an increase of 570.25% compared to the previous year's $13,433. Losses were -$26.81 million, 31.8% more than in 2020.

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for VNRX stock is "Buy." The 12-month stock price forecast is 7.75, which is an increase of 196.93% from the latest price.

Price Target
$7.75
(196.93% upside)
Analyst Consensus: Buy
Stock Forecasts

News

VolitionRx Limited Announces First Quarter 2022 Financial Results and Business Update

Conference call to discuss financial and operational results scheduled for Thursday, May 12, at 8:30 a.m. U.S. Eastern Time AUSTIN, Texas, May 11, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN:...

1 week ago - PRNewsWire

VolitionRx Limited Schedules First Quarter 2022 Earnings Conference Call and Business Update

Conference call to take place on Thursday May 12 at 08:30 a.m. Eastern Time Capital Markets Day Friday May 13 at 10:00 a.m.

1 week ago - PRNewsWire

VolitionRx Limited to Host Capital Markets Day on Friday May 13

AUSTIN, Texas , May 5, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") a multi-national epigenetics company plans to host a Capital Markets Day in a hybrid format on  Friday, ...

2 weeks ago - PRNewsWire

Volition Launches its Nu.Q® Vet Cancer Test in Asia Through its Appointed Distributor SAGE Healthcare

AUSTIN, Texas , April 25, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to h...

3 weeks ago - PRNewsWire

Volition appoints Sharon Ballesteros as U.S. Head of Quality and Development Process

AUSTIN, Texas , April 6, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has announced the appointment of Sharon Ballesteros as U.S Head...

1 month ago - PRNewsWire

VolitionRx Limited Announces Full Fiscal Year 2021 Financial Results and Business Update

Conference call to discuss financial and operational results scheduled for Thursday, March 31, at 8:00am U.S. Eastern Time ·        Executed global licensing and supply agreement with Heska Corporation ...

1 month ago - PRNewsWire

Heska Corporation Signs Exclusive Agreement to Introduce Nu.Q® Vet Cancer Screening Test, First-Ever Point of Care Ca...

LOVELAND, Colo. , March 29, 2022 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA) ("Heska"), a leading global provider of advanced veterinary diagnostics, has announced an exclusive global supply and li...

Other symbols:HSKA
1 month ago - PRNewsWire

Volition Signs Exclusive $28 million License and Supply Agreement with Heska Corporation to Distribute Nu.Q® Vet Canc...

AUSTIN, Texas, March 29, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has announced the signing of an exclusive global supply and lic...

Other symbols:HSKA
1 month ago - PRNewsWire

VolitionRx Limited Schedules Full Fiscal Year 2021 Earnings Conference Call and Business Update

Conference call to take place on Thursday March 31 at 08:00a.m. Eastern time AUSTIN, Texas, March 28, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will h...

1 month ago - PRNewsWire

Volition presents study data at ASCO GI 2022 on circulating nucleosomes for the detection of colorectal cancer and hi...

AUSTIN, Texas, Jan. 20, 2022 /PRNewswire/ --VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has announced the results of two large scale clinical studies, wh...

3 months ago - PRNewsWire

Volition Executes its First Supply and Licensing Contract for its Nu.Q® Vet Cancer Screening Test in Asia

SAGE Healthcare Private Limited appointed to serve as a non-exclusive licensee and distributor for Volition's Nu.Q® Vet Cancer Screening Test in centralized labs in Singapore, with launch planned in Sin...

5 months ago - PRNewsWire

VolitionRx Limited Announces Third Quarter 2021 Financial Results and Business Update

Conference call to discuss financial and operational results scheduled for Thursday, November 11, at 8:00 a.m. U.S. Eastern Time Healthy balance sheet with approximately $22.9 million in cash and cash e...

6 months ago - PRNewsWire

VolitionRx Limited Schedules Third Quarter 2021 Earnings Conference Call and Business Update

AUSTIN, Texas, Nov. 8, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call on Thursday, November 11, at 8:00 a.m. Eastern time to di...

6 months ago - PRNewsWire

Volition Veterinary Presents Two Posters at the 2021 Veterinary Cancer Society Conference

Positive data show Nu.Q® can be used to monitor for disease response and progression including remission monitoring in cancer bearing dogs. Paves the way for second Nu.Q® Vet product launch planned for ...

6 months ago - PRNewsWire

VolitionRx Limited Announces Second Quarter 2021 Financial Results and Business Update

Strong balance sheet with approximately $27.9 million in cash and cash equivalents Strengthened the Company's veterinary leadership team to drive commercial focus Expanded the Company's intellectual pro...

9 months ago - PRNewsWire

VolitionRx Limited Schedules Second Quarter 2021 Earnings Conference Call and Business Update

AUSTIN, Texas, Aug. 4, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call on Thursday, August 12, at 8:00 a.m. Eastern time to disc...

9 months ago - PRNewsWire

Volition's Nu.Q® NETs Assay Demonstrates Promising Results in COVID-19 Risk Stratification and Disease Monitoring

AUSTIN, Texas, July 22, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to hel...

9 months ago - PRNewsWire

VolitionRx Limited Announces First Quarter 2021 Financial Results and Business Update

Secured strongest-ever balance sheet with approximately $33.1 million in cash Strengthened the Company's leadership team to drive commercial focus Expanded the Company's intellectual property portfolio ...

1 year ago - PRNewsWire

VolitionRx Limited Schedules First Quarter 2021 Earnings Conference Call and Business Update

AUSTIN, Texas, May 6, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call on Wednesday May 12, at 8:00 a.m. Eastern time to discuss ...

1 year ago - PRNewsWire

VolitionRx Limited Announces Publication of Significant Nu.Q® Capture Mass Spectrometry Paper

AUSTIN, Texas, March 31, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to he...

1 year ago - PRNewsWire

VolitionRx Limited Appoints Dr. Tom Butera DVM as Chief Executive Officer for Volition Veterinary Subsidiary

AUSTIN, Texas, March 30, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to he...

1 year ago - PRNewsWire

VolitionRx Limited Appoints Two New Directors

AUSTIN, Texas, March 29, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to he...

1 year ago - PRNewsWire

VolitionRx Limited Announces Full Fiscal Year 2020 Financial Results and Business Update

Launched first product, the Nu.Q® Vet Cancer Screening Test and recorded first revenue from sales of a commercial product Engaged Diagnostic Oncology CRO LLC to conduct U.S. regulatory clinical trial fo...

1 year ago - PRNewsWire

New Data Demonstrates Nu.Q® is Effective in Monitoring Treatment of Sepsis

AUSTIN, Texas, March 17, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to he...

1 year ago - PRNewsWire

VolitionRx Limited Schedules Full Fiscal Year 2020 Earnings Conference Call and Business Update

AUSTIN, Texas, March 16, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call on Tuesday, March 23, at 8:00 a.m. Eastern time to disc...

1 year ago - PRNewsWire